UCB

BE0003739530

Pharmaceuticals

Market Closed - Euronext Bruxelles Other stock markets 11:35:16 2024-05-14 am EDT			5-day change	1st Jan Change
120.2 ^EUR	-1.47%		+0.29%	+52.41%

Apr. 11	Berenberg Reiterates UCB's Purchase Rating, Raises PT	MT
Apr. 11	UCB : Berenberg, Buy, raises its price target	CF

Belgian Pharmaceutical Company UCB Nominates Ulf Wiinberg to the Board

April 04, 2016 at 02:30 am EDT

Belgian Pharmaceutical Company UCB nominated Ulf Wiinberg to the board. Ulf has served on the boards of several healthcare industry associations.Ulf is non- executive board member at Alfa Laval, a Swedish industrial company, and Nestle Health and Science; he is also chairman of Avillion.

Latest news about UCB

Berenberg Reiterates UCB's Purchase Rating, Raises PT	Apr. 11	MT
UCB : Berenberg, Buy, raises its price target	Apr. 11	CF
UCB: new indication in sight for Bimzelx in the USA	Apr. 04	CF
UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx	Apr. 04	CI
UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies	Mar. 08	CI
UCB : UCB all set to reach new highs	Mar. 08
UCB Secures British Regulatory Nod for Generalized Myasthenia Gravis Treatment	Mar. 07	MT
South Korean Shares Close Higher After US Fed Chief Hints at Rate Cuts; Samsung Biologics Adds 1%	Mar. 07	MT
Samsung Biologics Strikes $353 Million Deal with Belgium's UCB	Mar. 07	MT
IMIDomics SL announced that it has received funding from UCB SA	Mar. 03	CI
Global markets live: Reckitt, Apple, Warner, Eli Llily, Intel...	Feb. 28
UCB : H2 beat; the prospects remain encouraging	Feb. 28
UCB SA Provides Earnings Guidance for the Year 2025	Feb. 28	CI
Transcript : UCB SA, 2023 Earnings Call, Feb 28, 2024	Feb. 28
UCB SA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
ZILBRYSQ® Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis in Adult Patients Who Are Anti-Acetylcholine Receptor Antibody Positive	Jan. 03	CI
Drugmakers set to raise U.S. prices on at least 500 drugs in January	Dec. 29	RE
UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society Annual Meeting	Dec. 02	CI
Strides Pharma Science Arm Gets US FDA's Nod for Generic Seizure Treatment	Nov. 21	MT
UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis	Nov. 14	CI
UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor	Nov. 11	CI
UCB Presents New Five-Year Data on Bimzelx® (Bimekizumab-Bkzx) in Ankylosing Spondylitis	Nov. 10	CI
UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio	Nov. 01	CI
UCB SA Announces Publication of NAYZILAM® Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function for People with Seizure Clusters	23-10-31	CI
Global markets live: United Airlines, General Motors, VMware, Nvidia, Exxon Mobil...	23-10-18

Chart UCB

Duration

Period

More charts

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Deutsche Bank R&D Call Series - Fireside Chat

Related indices

STOXX EUROPE 600 (EUR) , BEL-20

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

UCB : UCB all set to reach new highs

March 08, 2024 at 11:10 am EST

More Strategies

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

120.2 EUR

Average target price

125.5 EUR

Spread / Average Target

+4.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
UCB	+52.41%	25B
CSL LIMITED	-1.69%	89.37B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.65B
BIOGEN INC.	-12.32%	32.81B
BIOMARIN PHARMACEUTICAL INC.	-17.39%	15.29B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.45%	11.61B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.48%	11.49B
SWEDISH ORPHAN BIOVITRUM AB	+6.14%	8.98B
INNOVENT BIOLOGICS, INC.	-7.72%	8.23B
INTRA-CELLULAR THERAPIES, INC.	-8.25%	7B

Biopharmaceuticals

UCB

Equities

UCB

BE0003739530

Pharmaceuticals

Belgian Pharmaceutical Company UCB Nominates Ulf Wiinberg to the Board

EPS Revisions